Navigation Links
Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
Date:3/29/2013

SEATTLE, March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present at the 2013 Future Leaders in the Biotech Industry Conference.  Gregory A. Demopulos , M.D., chairman and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time on Friday, April 5, 2013.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. ... technologies company, today announced financial results for its first ... the three months ended December 31, 2014, revenue was ... quarter was $229,820 or $0.02 per share.  ... said "I am very pleased with the significant progress ...
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Finesse Solutions announced the expansion of its operations in ... planned for mid-March and access for customers is expected ... A-563, and located adjacent to the current office, the ... Finesse automation engineering team and allow Finesse to bring on ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2
... , PLYMOUTH MEETING, Pa., Nov. 20 ... article that questions why currently available medications designed to treat and ... organization, is offering a roadmap to the evidence on Finasteride ... , The November 13, 2009, New York Times article, ...
... , PRINCETON, N.J., Nov. 20 Soligenix, ... formerly known as DOR BioPharma, Inc., a late-stage biotechnology ... to develop thermostable technology to advance RiVax(TM) and other ... from the National Institute of Allergy and Infectious Diseases ...
Cached Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
(Date:3/2/2015)... 02, 2015 Secura Consultants announced ... with First Protective Insurance Group of Birmingham, AL ... First Protective affiliated advisors to access the enhanced ... Secura Consultants delivers. , Secura Consultants, ... in the design and implementation of insured income ...
(Date:3/1/2015)... 2015 As residents and business ... Michael Burns and Carita Weaver, believe in supporting ... with the Southlake Chamber of Commerce, Carroll Independent ... recently launched a website for Southlake mayoral candidate ... communications tool for Hill’s campaign, the website combines ...
(Date:3/1/2015)... 01, 2015 Comparing a new source ... using the Quotes Pros portal this year. A broad ... insurance rates that are being supplied through the finder ... agencies and prices available for each policy is now ... Every system user will first be asked to present ...
Breaking Medicine News(10 mins):Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2
... families are involved, study finds , FRIDAY, June 12 ... of an incurable genetic disease isn,t worry enough, people ... discriminated against by insurance companies, relatives and in social ... and colleagues at the University of British Columbia surveyed ...
... , ATLANTA, June 12 Salient Mobility LLC, ... of the 2009 " Text For a Cause(TM) " campaign, ... from organizations such as the Georgia Cancer Foundation . ... campaign begins August 24th, and culminates with the issuance of ...
... 12 June 2009: Three new studies have individually shown ... effective, with a good safety profile, in children under ... and associated with improved Health-Related Quality of Life (HRQoL) ... data are being presented at the Paediatric Rheumatology European ...
... five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% ... benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ... AS patients had no arthritis and 84.9% had no ... Over this period, patients continued to show a sustained ...
... National Quality Forum (NQF) has tapped Thomas B. Valuck, ... Strategic Partnerships. Dr. Valuck comes to NQF from the ... was both Medical Officer and Senior Adviser in the ... a unique, multi-stakeholder, nonprofit organization dedicated to improving the ...
... Medifast, Inc. (NYSE: MED ) today announced ... corporate-owned Medifast Weight Control Centers. Earlier in the year, the ... out, and analyze the success of the model throughout the ... be expanding its investment in this area. , , ...
Cached Medicine News:Health News:People With Huntington's Report Discrimination 2Health News:People With Huntington's Report Discrimination 3Health News:Salient Mobility Launches the 'Text For a Cause(TM)' Campaign in Raising Awareness Through Wireless Health Tips 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 2Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 3Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: